Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 7/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 6/20 | 0.45 |
| ▸ | HTR1A | P08908 | 5/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | HTR6 | P50406 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2780942 | 1.00 | SLC6A4 (0.54) | SLC6A4OPRM1OPRK1OPRL1DRD2 | |
| SCHEMBL2781828 | 0.89 | HTR1A (0.53) | SLC6A4OPRM1OPRL1DRD2HTR1A | |
| Hydrochloric Acid SCHEMBL2779321 | 0.89 | HTR1A (0.53) | SLC6A4OPRM1OPRL1DRD2HTR1A | |
| Hydrochloric Acid SCHEMBL2779988 | 0.88 | HTR1A (0.56) | SLC6A4OPRL1DRD2HTR1AHTR6 | |
| SCHEMBL2780912 | 0.88 | HTR1A (0.56) | SLC6A4OPRL1DRD2HTR1AHTR6 | |
| SCHEMBL13228814 | 0.82 | MAPT (0.51) | SLC6A4OPRM1OPRK1DRD2HTR1A | |
| Hydrochloric Acid SCHEMBL2780984 | 0.81 | OPRL1 (0.56) | SLC6A4OPRM1OPRK1OPRL1HTR1A | |
| Hydrochloric Acid SCHEMBL2780538 | 0.80 | MAPT (0.49) | SLC6A4OPRM1OPRK1DRD2HTR1A | |
| SCHEMBL2784123 | 0.80 | MAPT (0.49) | SLC6A4OPRM1OPRK1DRD2HTR1A | |
| SCHEMBL2781470 | 0.79 | OPRL1 (0.57) | SLC6A4OPRM1OPRK1OPRL1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560823-B1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2008-07-09 | — | — | EP | claimed |
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2005-12-15 | — | — | US | claimed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| US-7759385-B2 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2010-07-20 | — | — | US | disclosed |
| EP-1560823-B1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | GRUENENTHAL GMBH (DE) | 2008-07-09 | — | — | EP | disclosed |
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | GRUENENTHAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| EP-1560823-A1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2005-08-10 | — | — | EP | disclosed |
| WO-2004043949-A1 | 4-SUBSTITUTED 1-AMINOCYCLOHEXANE DERIVATIVES FOR UTILIZATION AS ORL1-RECEPTOR AND MU-OPIATE RECEPTOR LIGANDS | Grünenthal GmbH (DE) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277674-A1 | 4-substituted 1-aminocyclohexane compounds for utilization as ORL1-receptor and mu-opiate receptor ligands | OPRL1, OPRM1, OGFRL1 | SLC6A4 1068/4885OPRM1 2/4885OPRK1 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.